Tag: clinical trial

Moderna mRNA RSV vaccine proves effective for older adults

Editor’s note Moderna’s mRNA-based RSV vaccine is effective in preventing RSV-associated lower-respiratory tract disease in adults aged 60 an older, according to randomized phase II-III trial results published December 14 in The New England Journal of Medicine. Results also confirmed the safety of a single dose of the vaccine, researchers…

Read More

By: Matt Danford
December 22, 2023
Share

Senate appoints oncologist, cancer researcher as NIH director

Editor's Note The US Senate has appointed Monica Bertagnolli, MD, as the new director of the National Institutes of Health (NIH), the agency’s first permanent leader in nearly 2 years and the second woman to hold the post. She is expected to face significant scrutiny from lawmakers, Chief Healthcare Executive…

Read More

By: Brita Belli
November 17, 2023
Share

Concerted push for greater diversity in medical studies ongoing

Editor's Note Although Congress first required the National Institutes of Health to include more women and people of color in medical studies in 1993, progress has been slow until recently. Now, researchers are making a concerted effort to diversify medical studies, The Wall Street Journal (WSJ) November 16 reports.  According…

Read More

By: Brita Belli
November 16, 2023
Share

Video laryngoscopy leads to higher success rates than direct laryngoscopy

Editor's Note Video laryngoscopy was found to lead to higher intubation success rates over direct laryngoscopy in critically ill adult patients, an August 2023 randomized controlled trial published by the The New England Journal of Medicine shows. The findings were consistent whether they were intubated in an emergency room or…

Read More

By: Brita Belli
October 30, 2023
Share

Improving underrepresented patient participation in clinical trials: It matters who makes the request

Editor's Note In this investigative study done by the Boston Medical Center (BMC), patients were shown more likely to agree to participate in clinical studies when approached by research staff of the same race or ethnicity as them. The findings were published in JAMA Ophthalmology on October 19.  The study…

Read More

By: Brita Belli
October 20, 2023
Share

Survival rates strong following low-risk cardiac surgery

Editor's Note A new study in the Annals of Thoracic Surgery finds that long-term survival rates are extremely promising for patients who receive low-risk isolated surgical aortic valve replacement (SAVR). The study, titled "Survival Following Surgical Aortic Valve Replacement in Low-Risk Patients: A Contemporary Trial Benchmark," was published on October…

Read More

By: Brita Belli
October 18, 2023
Share

Limiting opioid medication did not negatively impact patients post-surgery

Editor's Note A 5-day limit on opioid pain medication prescriptions in Michigan did not negatively impact patient-reported pain levels or satisfaction, JAMA Network October 13 reports. The study, titled "Changes in surgical opioid prescribing and patient-reported outcomes after implementation of an insurer opioid prescribing limit," was published by JAMA Health…

Read More

By: Brita Belli
October 16, 2023
Share

First nasal vaccine in development for deadly Strep A

Editor's Note A new nasal vaccine in development by Griffith University’s Institute for Glycomics in Australia could provide long-term protection against the deadly bacteria Streptococcus A (Strep A), Griffith University's Griffith News October 5 reports. Strep A causes 700 million human infections each year, and there are more than 500,000…

Read More

By: Brita Belli
October 9, 2023
Share

AI brain implants allow paralyzed man to regain use of arms, hands, fingers

Editor's Note In a first of its kind surgical procedure, doctors have installed artificial intelligence (AI) implants in the brain of a 46-year-old man who was paralyzed from a fall on the ice, CNN September 27 reports. The AI implant formed a "digital bridge"–an idea pioneered by the French neuroscientist…

Read More

By: Brita Belli
September 28, 2023
Share

Benefits seen in phase 3 of Alzheimer's drug trial

Editor's Note Eisai, the Japanese drug maker, said on Tuesday September 27, that its experimental drug for Alzheimer’s disease helped slow cognitive decline to those experiencing early stages of the illness. In the phase 3 clinical trials, the drug, called lecanemab, slowed cognitive decline by 27% after 18 months, the…

Read More

By: Lauren McCaffrey
September 28, 2022
Share

Join our community

Learn More
Video Spotlight
Live chat by BoldChat